VivoSim Labs (VIVS) Competitors $1.74 0.00 (-0.11%) As of 08/8/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock VIVS vs. CLDI, CVKD, LSTA, NAII, VYNE, PASG, ELEV, RLMD, RLYB, and BCABShould you be buying VivoSim Labs stock or one of its competitors? The main competitors of VivoSim Labs include Calidi Biotherapeutics (CLDI), Cadrenal Therapeutics (CVKD), Lisata Therapeutics (LSTA), Natural Alternatives International (NAII), VYNE Therapeutics (VYNE), Passage Bio (PASG), Elevation Oncology (ELEV), Relmada Therapeutics (RLMD), Rallybio (RLYB), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. VivoSim Labs vs. Its Competitors Calidi Biotherapeutics Cadrenal Therapeutics Lisata Therapeutics Natural Alternatives International VYNE Therapeutics Passage Bio Elevation Oncology Relmada Therapeutics Rallybio BioAtla Calidi Biotherapeutics (NYSE:CLDI) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Which has better valuation & earnings, CLDI or VIVS? VivoSim Labs has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi BiotherapeuticsN/AN/A-$29.22MN/AN/AVivoSim Labs$140K32.41-$2.48M-$10.20-0.17 Does the media prefer CLDI or VIVS? In the previous week, Calidi Biotherapeutics had 3 more articles in the media than VivoSim Labs. MarketBeat recorded 3 mentions for Calidi Biotherapeutics and 0 mentions for VivoSim Labs. VivoSim Labs' average media sentiment score of 0.00 beat Calidi Biotherapeutics' score of -1.00 indicating that VivoSim Labs is being referred to more favorably in the news media. Company Overall Sentiment Calidi Biotherapeutics Negative VivoSim Labs Neutral Do insiders and institutionals believe in CLDI or VIVS? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 3.7% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is CLDI or VIVS more profitable? Calidi Biotherapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,725.00%. Calidi Biotherapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% VivoSim Labs -1,725.00%-46.87%-28.62% Which has more volatility & risk, CLDI or VIVS? Calidi Biotherapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. SummaryCalidi Biotherapeutics beats VivoSim Labs on 6 of the 10 factors compared between the two stocks. Get VivoSim Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricVivoSim LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.54M$2.97B$5.45B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio-0.1716.9029.7824.84Price / Sales32.41313.57450.0698.72Price / CashN/A41.8536.4258.36Price / Book0.317.318.185.65Net Income-$2.48M-$54.43M$3.26B$265.77M7 Day Performance-5.68%0.01%6.11%4.62%1 Month Performance-7.92%1.33%0.92%0.77%1 Year PerformanceN/A8.65%28.84%22.14% VivoSim Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSVivoSim LabsN/A$1.75-0.1%N/AN/A$4.54M$140K-0.1720Gap UpCLDICalidi Biotherapeutics0.1634 of 5 stars$0.63+14.9%N/A-75.1%$22.94MN/A0.0038Negative NewsHigh Trading VolumeCVKDCadrenal Therapeutics2.2962 of 5 stars$10.87-6.1%$32.00+194.4%N/A$22.77MN/A-1.174Positive NewsLSTALisata Therapeutics3.0407 of 5 stars$2.57-2.3%$23.50+814.4%-13.9%$22.66M$1M-1.1230News CoverageEarnings ReportGap DownNAIINatural Alternatives InternationalN/A$3.70+2.8%N/A-30.7%$22.24M$113.80M-2.66290Positive NewsVYNEVYNE Therapeutics2.69 of 5 stars$1.44-0.7%$6.25+334.0%-79.8%$22.05M$500K-1.4530Upcoming EarningsPASGPassage Bio3.3969 of 5 stars$6.34-10.1%$150.00+2,265.9%-59.8%$22MN/A-0.31130News CoverageUpcoming EarningsELEVElevation Oncology2.2803 of 5 stars$0.37flat$3.39+827.6%N/A$21.62MN/A-0.4540RLMDRelmada Therapeutics4.5249 of 5 stars$0.63-2.3%$5.00+699.5%-74.5%$21.26MN/A-0.2510News CoverageNegative NewsEarnings ReportAnalyst UpgradeRLYBRallybio2.6048 of 5 stars$0.47-6.7%$10.00+2,026.8%-55.4%$20.96M$640K-0.4340News CoveragePositive NewsEarnings ReportBCABBioAtla1.7729 of 5 stars$0.35-1.8%$5.00+1,338.4%-76.0%$20.68M$11M-0.2860News CoveragePositive NewsEarnings Report Related Companies and Tools Related Companies Calidi Biotherapeutics Alternatives Cadrenal Therapeutics Alternatives Lisata Therapeutics Alternatives Natural Alternatives International Alternatives VYNE Therapeutics Alternatives Passage Bio Alternatives Elevation Oncology Alternatives Relmada Therapeutics Alternatives Rallybio Alternatives BioAtla Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
